A year after a common heartburn ingredient was linked to a contaminant and worldwide recalls followed, concerns have emerged in the US that products in the category could weaken the efficacy of other drugs or cause adverse events when used at the same time.
A Food and Drug Administration draft guidance on testing investigational drugs for drug-drug interactions (DDIs) with ingredients used in...




